Lenalidomide Capsule
Product Images NDC 43598-511

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 43598-511). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy's Laboratories Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container1 (Container1)

The label for Lenalidomide Capsules 2.5 mg by Dr. Reddy's Laboratories Inc. displays the active ingredient strength prominently in orange text. It includes a warning about potential human birth defects and lists a package size of 28 capsules. The label features a barcode, NDC number 43598-516-63, and storage instructions.*

FDA Label Image

Container2 (Container2)

Lenalidomide Capsules 5 mg oral capsules label by Dr. Reddy's Laboratories Inc., displaying a warning about potential human birth defects. The package contains 28 capsules and includes storage and dispensing instructions alongside manufacturer information, NDC 43598-511-63.*

FDA Label Image

Container3 (Container3)

Label for Lenalidomide Capsules 10 mg by Dr. Reddy's Laboratories Inc. The label states the product is prescription only with NDC 43598-512-63. It contains 28 capsules and includes a warning about potential human birth defects. Additional storage and manufacturer details are printed alongside a barcode.*

FDA Label Image

Container4 (Container4)

Label for Lenalidomide Capsules 15 mg oral capsules by Dr. Reddy's Laboratories Inc. The label includes a warning about potential human birth defects and states a package size of 21 capsules. It features the NDC number 43598-513-21 and storage information to keep the product at 20 to 25 degrees Celsius, protected from moisture and light. The label also displays a barcode and indicates the product is made in India.*

FDA Label Image

Container5 (Container5)

Packaging label for Lenalidomide Capsules 20 mg by Dr. Reddy's Laboratories Inc. The label indicates it contains 21 capsules, is prescription only, and provides warnings including potential for human birth defects. Includes NDC 43598-514-21 and storage instructions, with a barcode and manufacturing details.*

FDA Label Image

Container6 (Container6)

Label for Lenalidomide Capsules 25 mg by Dr. Reddy's Laboratories Inc. The label includes dosage information, a warning about human birth defects, prescription status, NDC code, and a barcode. The package contains 21 capsules.*

FDA Label Image

Fig3 (Fig3)

A Kaplan-Meier survival curve comparing time to progression in months between treatment groups: Lenalidomide/Dex and Placebo/Dex. The Y-axis shows the proportion of subjects, and the graph includes hazard ratio (HR) with 95% confidence interval and a p-value for the log-rank test.*

FDA Label Image

Fig4 (Fig4)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months. It compares two groups: Lenalidomide/Dex (in blue) and Placebo/Dex (in black), depicting time to disease progression. The chart includes hazard ratio (HR) and confidence interval (CI) statistics with a log-rank p-value.*

FDA Label Image

Figure10 (Figure10)

A Kaplan-Meier survival probability curve showing progression-free survival over 48 months for two groups: one treated with Rituximab plus Lenalidomide and the other with Rituximab plus placebo. The y-axis represents survival probability, and the x-axis shows progression-free survival in months. A table below lists the number of subjects at risk at various time points for both groups.*

FDA Label Image

Figure5 (Figure5)

A Kaplan-Meier survival curve chart illustrating progression-free survival probabilities over 60 months for Lenalidomide treatment groups: 'Rd Continuous' (solid blue line), 'Rd18' (dashed green line), and 'MPT' (dashed red line). The chart includes hazard ratios, confidence intervals, a logrank p-value, and a number of subjects at risk table below the graph.*

FDA Label Image

Figure6 (Figure6)

A Kaplan-Meier survival curve chart illustrating overall survival probability (%) over time in months for three groups labeled Rd Continuous, Rd18, and MPT. The chart includes hazard ratios with 95% confidence intervals comparing these groups. A table below the x-axis displays the number of subjects at risk at various time points for each group.*

FDA Label Image

Figure7 (Figure7)

A Kaplan-Meier survival curve comparing Lenalidomide versus placebo. The graph shows the probability of survival over time (months) with a higher survival probability for Lenalidomide depicted by a solid blue line compared to placebo with a dashed red line. The chart includes hazard ratio, confidence intervals, and median survival times.*

FDA Label Image

Figure8 (Figure8)

A data table presenting numerical values arranged in two rows under several columns. The table likely shows comparative data points but does not include visible labels for the rows or columns.*

FDA Label Image

Figure9 (Figure9)

A Kaplan-Meier plot comparing survival probability over time (in months) between Lenalidomide and placebo groups. The graph shows progression-free survival, with Lenalidomide represented by a blue line and placebo by a red dashed line, including a number of subjects at risk at various time points and a hazard ratio with confidence intervals noted.*

FDA Label Image

Structure (Structure)

Chemical structure of lenalidomide, showing its molecular framework with two rings, including an amino group and carbonyl groups, consistent with its chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.